Please assess the completion status of the following clinical trial:

Trial Title: Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Indications for cardiac surgery (CABG, valve surgery or CABG and valve surgery, Able to provide informed consent.~Exclusion Criteria:~* Documented atrial fibrillation within the previous 3 months~* Ongoing therapy with suppressive antiarrhythmic drugs~* Patient currently on digoxin~* Emergent surgery~* Patient receiving hemodialysis~* Concomitant use of ketoconazole, diltiazem, verapamil~* Known tolerance or hypersensitivity to ranolazine~* Pregnant individuals~* MAZE procedure (is a surgical ablation to treat atrial fibrillation) performed during concurrent cardiac surgery

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CABG surgery with Ranolazine (Type: ACTIVE_COMPARATOR): Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Ranolazine 1000 mg (2-500mg tablets) twice daily. If intolerant to the study drug due to adverse effects,or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice daily.
- CABG surgery with placebo (Type: PLACEBO_COMPARATOR): Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Placebo 1000mg mg (2-500mg tablets)twice daily. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily.
- Heart Valve surgery with Ranolazine (Type: ACTIVE_COMPARATOR): Patient will undergo heart Valve surgery and will receive, Ranolazine1000mg (2-500 mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice a day.
- Heart Valve surgery with placebo (Type: PLACEBO_COMPARATOR): Patient will undergo heart Valve surgery and will receive, Placebo 1000mg (2-500mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).